Pricing Log in Create free account
Friday 6 November 2026 Export ALKS’s income statement to Excel — free account

Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue
+21.8%
EPS
−80.6%
Free cash flow
+6.78%

Quarter to September 2026, against a year earlier

44.61 1.28 −2.79%
Market cap
$7.5B
P/E
0.0×
Fwd P/E
−85.9×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Alkermes plc (ALKS) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Alkermes plc (ALKS) trades at a EV/EBITDA of 37.9×. Over the past ten years it has ranged from 0.0× (June 2021) to 1,105× (March 2019); the current reading is higher than 80% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 12.2× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 12.7× 33.13%
FY2024 9.6× 9.37%
FY2023 8.7× (82.71%)
FY2022 50.5× 174.85%
FY2021 18.4× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 883× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 34.7× (19.48%)
Jun 2026 43.1× 52.89%
Mar 2026 28.2× 121.59%
Dec 2025 12.7× 19.77%
43 more quarters

Against its own ten years

Low 0.0× High 1,105×
Ten-year median 7.0×
Current reading's percentile 80

EV/EBITDA against peers

Company EV/EBITDA
HIMS Hims & Hers Health, Inc. compare n/m
SUPN Indivior Pharmaceuticals Inc. compare 7.0×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 14.3×
LNTH Lantheus Holdings, Inc. compare 16.7×
ELAN Elanco Animal Health Incorporated compare 19.7×
LQDA Liquidia Corporation compare 22.7×
RDY Dr. Reddy's Laboratories Ltd compare 22.9×
ALKS Alkermes plc 37.9×
KNSA Kiniksa Pharmaceuticals International, plc compare 48.0×
Drug Manufacturers Specialty & Generic industry median 12.2×
Healthcare sector median 8.4×
Market median 10.9×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on ALKS